UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Nicole Paulk, PhD

Title(s)Assistant Professor, Biochemistry and Biophysics
SchoolSchool of Medicine
ORCID ORCID Icon0000-0002-5557-6280 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityPostdoc08/2016Human Gene Therapy
    Oregon Health & Science UniversityPhD06/2012Viral Gene Therapy and Liver Regeneration
    Central Washington UniversityBS06/2006Medical Microbiology

    Collapse Overview 
    Collapse Overview
    For patients seeking treatment for rare genetic diseases and cancer, the standard of care can often be invasive (e.g. organ transplantation or surgical debulking) or temporary (e.g. enzyme replacement therapy or chemotherapy). AAV gene therapies are attractive alternatives as they are non-invasive with long-term therapeutic benefits. However, the success of this new generation of transformative therapies is critically dependent on delivery, efficacy, safety and cost. In the Paulk lab we engineer disruptive technologies to directly address each of these to make AAV cheaper, easier and faster to get these life-saving drugs to the patients who need them.

    Collapse Research 
    Collapse Research Activities and Funding
    Characterizing the proteomic landscape of rAAV vectors for human liver gene therapies.
    AMERICAN SOCIETY OF GENE & CELL THERAPY Dec 12, 2018 - Dec 11, 2019
    Role: Principal Investigator
    Human microtissues for in vitro detection and functional measurement of adverse consequences caused by genome editing.
    NIH/OD U01-HL145795Sep 25, 2018 - Jun 30, 2023
    Role: Co-Investigator
    Development of Experimental Viral Gene Therapies for Glioblastoma.
    Role: Co-PI
    Sexually dimorphic viral-host interactions in pediatric liver diseases.
    Role: Principal Investigator
    Overcoming sexually dimorphic barriers to viral gene therapy for treating genetic liver diseases
    NIH/NIDDK K01DK107607Aug 4, 2016 - May 31, 2021
    Role: Principal Investigator
    Characterizing whether clinical and research-grade rAAV vectors differ in post-translational modifications.
    Role: Co-PI
    Novel strategies to expand the adeno-associated virus platform.
    NIH/NHLBI F32HL119059Jun 19, 2014 - Jun 18, 2017
    Role: Principal Investigator
    Determining the Progenitor-Like Capacity of Liver Cancer Cells in vivo.
    NIH/NCI F31CA130116Sep 1, 2007 - May 31, 2012
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Maynard LH, Smith O, Tilmans NP, Tham E, Hosseinzadeh S, Tan W, Leenay R, May AP, Paulk NK. Fast-Seq: A Simple Method for Rapid and Inexpensive Validation of Packaged Single-Stranded Adeno-Associated Viral Genomes in Academic Settings. Hum Gene Ther Methods. 2019 Dec; 30(6):195-205. PMID: 31855083.
      View in: PubMed
    2. Rumachik NG, Malaker SA, Poweleit N, Maynard LH, Adams CM, Leib RD, Cirolia G, Thomas D, Stamnes S, Holt K, Sinn P, May AP, and Paulk NK.. Methods Matter -- Standard Production Platforms For Recombinant AAV Can Produce Chemically And Functionally Distinct Vectors. BioRxiv. 2019.
    3. Oh Y, Park Y, Cho JH, Wu H, Paulk NK, Liu LX, Kim N, Kay MA, Wu JC, Lin MZ. An orange calcium-modulated bioluminescent indicator for non-invasive activity imaging. Nat Chem Biol. 2019 05; 15(5):433-436. PMID: 30936501.
      View in: PubMed
    4. Paulk NK, Pekrun K, Charville GW, Maguire-Nguyen K, Wosczyna MN, Xu J, Zhang Y, Lisowski L, Yoo B, Vilches-Moure JG, Lee GK, Shrager JB, Rando TA, Kay MA. Bioengineered Viral Platform for Intramuscular Passive Vaccine Delivery to Human Skeletal Muscle. Mol Ther Methods Clin Dev. 2018 Sep 21; 10:144-155. PMID: 30101152.
      View in: PubMed
    5. Winters IP, Chiou SH, Paulk NK, McFarland CD, Lalgudi PV, Ma RK, Lisowski L, Connolly AJ, Petrov DA, Kay MA, Winslow MM. Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nat Commun. 2017 12 12; 8(1):2053. PMID: 29233960.
      View in: PubMed
    6. Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, Collaud F, Simon-Sola M, Charles S, Hardet R, Leborgne C, Meliani A, Cohen-Tannoudji M, Astord S, Gjata B, Sellier P, van Wittenberghe L, Vignaud A, Boisgerault F, Barkats M, Laforet P, Kay MA, Koeberl DD, Ronzitti G, Mingozzi F. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid a-glucosidase. Sci Transl Med. 2017 Nov 29; 9(418). PMID: 29187643.
      View in: PubMed
    7. Paulk NK, Pekrun K, Zhu E, Nygaard S, Li B, Xu J, Chu K, Leborgne C, Dane AP, Haft A, Zhang Y, Zhang F, Morton C, Valentine MB, Davidoff AM, Nathwani AC, Mingozzi F, Grompe M, Alexander IE, Lisowski L, Kay MA. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol Ther. 2018 01 03; 26(1):289-303. PMID: 29055620.
      View in: PubMed
    8. Barzel A, Paulk NK, Shi Y, Huang Y, Chu K, Zhang F, Valdmanis PN, Spector LP, Porteus MH, Gaensler KM, Kay MA. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature. 2015 Jan 15; 517(7534):360-4. PMID: 25363772.
      View in: PubMed
    9. Paulk NK, Wursthorn K, Haft A, Pelz C, Clarke G, Newell AH, Olson SB, Harding CO, Finegold MJ, Bateman RL, Witte JF, McClard R, Grompe M. In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice. Mol Ther. 2012 Oct; 20(10):1981-7. PMID: 22871666.
      View in: PubMed
    10. Paulk NK, Loza LM, Finegold MJ, Grompe M. AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo. Hum Gene Ther. 2012 Jun; 23(6):658-65. PMID: 22486314.
      View in: PubMed
    11. Taylor AM, Preston AJ, Paulk NK, Sutherland H, Keenan CM, Wilson PJ, Wlodarski B, Grompe M, Ranganath LR, Gallagher JA, Jarvis JC. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis Cartilage. 2012 Aug; 20(8):880-6. PMID: 22542924.
      View in: PubMed
    12. Paulk NK.. Novel strategies to improve viral gene targeting and therapeutic liver repopulation in vivo. 2012.
    13. Paulk NK, Wursthorn K, Wang Z, Finegold MJ, Kay MA, Grompe M. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology. 2010 Apr; 51(4):1200-8. PMID: 20162619.
      View in: PubMed
    14. Duncan AW, Hickey RD, Paulk NK, Culberson AJ, Olson SB, Finegold MJ, Grompe M. Ploidy reductions in murine fusion-derived hepatocytes. PLoS Genet. 2009 Feb; 5(2):e1000385. PMID: 19229314.
      View in: PubMed
    15. Key J, Paulk N, and Johansen A.Effects of DMSO oxidation products on iron speciation in photochemical simulation experiments. Environ Sci Technol. 2008; 1(42):133-139.
    16. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 2007 Aug; 25(8):903-10. PMID: 17664939.
      View in: PubMed
    Nicole's Networks
    Derived automatically from this person's publications.
    People in Profiles who have published with this person.
    Similar People
    People who share similar concepts with this person.
    Same Department